Stockreport

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc.  (BMEA) 
PDF Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucag [Read more]